Core Viewpoint - Kolon Biotech Inc. (06990) experienced a significant increase in stock price, rising by 5.37% to HKD 483, with a trading volume of HKD 1.5939 million, following the announcement of multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21 [1]. Group 1 - Kolon Biotech announced the presentation of several clinical research results at the ESMO conference [1]. - The research included data on targeted antibody-drug conjugates (ADCs) such as sac-TMT (佳泰莱), A166 (舒泰莱), and SKB315 [1]. - The focus of the studies was on TROP2, HER2, and Claudin18.2 [1].

Core Viewpoint - The company announced that its subsidiary, Sichuan Kelun-Botai Biopharmaceutical Co., Ltd., presented multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21 [1] Group 1 - The clinical research results include data on targeted antibody-drug conjugates (ADCs) such as sac-TMT (Jiatailai), targeting trophoblast cell surface antigen 2 (TROP2) [1] - The company also presented data on A166 (Shutailai), a HER2-targeted ADC [1] - Additionally, results related to Claudin18.2 (CLDN18.2) ADC SKB315 were shared [1]

Core Viewpoint - The company announced the presentation of multiple clinical research results at the 2025 European Society for Medical Oncology (ESMO) conference held in Berlin from October 17 to 21, focusing on various antibody-drug conjugates (ADCs) targeting specific cancer markers [1] Group 1: Clinical Research Results - The company presented data on the TROP2-targeted ADC sac-TMT (佳泰莱) [1] - The company showcased results for the HER2-targeted ADC A166 (舒泰莱) [1] - The company also reported findings related to the Claudin18.2-targeted ADC SKB315 [1]